ProvecTEST™
分析腫瘤單細胞抗藥性，鎖定最佳治療組合方案
Analyzing tumor single-cell drug resistance
to identify the optimal combination therapy.
Official launch in the Hong Kong and Macau regions
在香港及澳門市場正式發佈
Phase I : Breast Cancer Patient
第一階段：乳癌患者
Beyond Standard Guidelines. Toward Cancer Treatment
分析腫瘤抗藥性，邁向精準個人化治療
Consult with physicians for further information
向相關醫生諮詢專業臨床意見
If you are interested in learning more about ProvecTEST™ and predicting treatment response rates, please contact our service distributor, Allevia Life Sciences, via the following channels:
如有興趣了解 ProvecTEST™ 並預測治療反應率，
請透過以下方式聯絡我們的服務經銷夥伴 Allevia Life Sciences：
Email : lab@alleviahk.com
WhatsApp : +852 9851 6284
Live Clinical Sample Collection & Transportation
活體臨床樣本採集與運輸
Live tumour biopsy samples are collected under optimal conditions and transported to our laboratory for processing. The total transport and handling time is maintained within 2 to 8 hours to preserve cell viability and analytical integrity.
活體腫瘤活檢樣本會在最佳條件下採集和保存，並運送至本公司期下香港科學園實驗室進行處理。整體運輸及處理時間控制於一個工作天內，以確保細胞活性及藥物測試報告穩定性。
Single Cell Drug Screening & Analysis
單細胞藥物篩選與分析
Live tumour cells are analyzed at the single‑cell level to evaluate drug sensitivity and resistance. By measuring functional responses toward different therapeutic agents , the platform generates actionable insights to support personalized treatment selection and predict response variability.
活體腫瘤細胞會於單細胞層級進行分析，以評估異質性細胞族群中的藥物敏感性與抗藥性。透過同步量測多種治療藥物，該平台可產生具臨床應用價值的獨有資訊，支援個人化治療選擇並預測患者治療反應。
Comprehensive Treatment Plan Review
全面治療方案評估
ProvecTEST™ delivers high‑resolution single‑cell drug resistance profiles, revealing hidden tumour heterogeneity for clinicians and pathologists. By integrating with standard pathological reports and clinical data, optimal treatment plan would be suggested. by clinicians.
ProvecTEST™ 提供高解析度單細胞藥物抗性分析結果，辨認腫瘤中潛在異質性，供臨床醫生及病理學家參考。透過結合標準病理報告及臨床資料後，臨床醫生可據此建議個人化的新型治療方案。
Explore ProvecTEST™
for your Tailored Cancer Treatment
探索 ProvecTEST™
打造專屬您的癌症治療方案
We invite breast cancer patients in Hong Kong and Macau Region, particularly patient shown resistance to current treatments,to participate in our 2026 Pilot Service .
我們誠摯邀請在香港和澳門地區的乳癌患者，特別是曾對治療產生抗藥性的患者，
考慮參與2026年度的資助計劃
In 2026, Provectus Therapeutics and Allevia Life Sciences will jointly provide over HKD 6 million in subsidies for breast cancer patients in Hong Kong and Macau, offering free or up to 90%‑subsidized testing to support personalized cancer treatment.
Please consult your doctor for further details.
於 2026 年，Provectus Therapeutics 與 Allevia Life Sciences 將合共提供超過港幣 600 萬元資助，為香港及澳門乳癌患者提供免費或最高九折資助的檢測服務，以支援個人化癌症治療。
詳情請向主診醫生查詢。